Strata Critical Medical (SRTA): The Organ Transplant Logistics Roll-Up

In this Business Breakdown, David Barbato and Adam Wilk sit down with Strata Critical Medical’s (SRTA) co-CEO and CFO Will Heyburn and VP of Finance and Investor Relations and CFO of Clinical Services, Mat Schneider.

This discussion took place live on September 29th, 2026, on the MicroCapClub Community. Join MicroCapClub and unlock the ability to listen and participate live in these discussions - microcapclub.com/#join

Will Heyburn is co-CEO and CFO of Strata Critical Medical (SRTA), which provides air and ground logistics and clinical services to the US organ transplant industry and supports open heart surgeries at more than 250 hospitals. Before Strata, he worked in private equity at RedBird Capital Partners, and he has been part of the transplant business since it started in 2019. He is joined by Mat Schneider, VP of Finance and Investor Relations and CFO of Clinical Services, who spent twelve years on the buy side.

✉️ Share your feedback - david@microcapclub.com
✉️ David’s X (Twitter) - x.com/Valuehunte

Chapters

00:00 Introduction to Strata and its mission
03:10 Overview of Strata's services in organ transplant
07:00 Strata's role in organ placement and recovery
11:10 Growth in donation after circulatory death and perfusion
12:38 Advancements in matching algorithms and logistics challenges
14:30 Market share, partnerships, and growth opportunities
16:00 Impact of regulatory changes and industry trust
17:28 Acquisition strategy and integration of clinical and logistics services
20:01 Financial performance and growth metrics
21:17 Industry evolution and competitive landscape
24:37 Device agnosticism and future industry trends
26:48 Competitive advantages of Strata's model
29:46 Pricing, RFPs, and market positioning
34:08 Aircraft ownership and logistics infrastructure
38:24 Industry growth outlook and future opportunities
41:26 Penetration of normothermic regional perfusion and clinical growth
43:40 Regulatory environment and trust in the system
46:45 Third-party recovery market share and growth
50:15 Inorganic growth, return thresholds, and strategic fit
57:12 Long-term vision and industry evolution

Disclaimer: All content on this channel is for discussion, education, entertainment, and illustrative purposes only and SHOULD NOT be construed as professional financial advice, solicitation, or recommendation to buy or sell any securities, notwithstanding anything stated on this channel. There are risks associated with investing in securities. Loss of principal is possible. Past performance is not a predictor of future investment performance. Ian Cassel and the guests on this channel are not responsible for investment actions taken by viewers. Should you need such advice, consult a licensed financial advisor, legal advisor, or tax advisor. You agree to verify all information yourself before investing. Any past performance discussed during this program is no guarantee of future results. Investing involves risk and possible loss of principal capital; please seek advice from a licensed professional. All views expressed are personal opinions as of the date of recording and are subject to change without the responsibility to update views. No guarantee is given regarding the accuracy of the information on this channel. Releasees undertake no obligation to provide accurate or sound investment statements. You waive any and all duties that may exist flowing from you to any Releasee. You agree not to hold any Releasee liable for any possible claim for damages arising from any decision you make based on information or other content on the Channel.